<p>药明康德集团股票（NASDAQ:PHAR - 获取免费报告）周三交易量不寻常地高。大约有 10,737 股在午间交易时交易，较前一交易日的 4,336 股增加了 148%。该股最新交易价为$8.18，之前收盘价为$7.82。</p>
<p>获取 <strong>药明康德集团</strong> 警报：</p>
<h2>华尔街分析师观点</h2>
<p>另外，HC Wainwright 重申了对药明康德集团股票的 “买入” 评级，并在 8 月 1 日星期四的研究报告中发布了 37.00 美元的目标价。</p>
<p><strong>查看我们对药明康德集团的最新研究报告</strong></p>
<h2>药明康德集团股价上涨 4.6%</h2>
<p>该公司市值为 5.5087 亿美元，市盈率为-48.88，β系数为 0.15。公司的流动比率为 3.39，速动比率为 2.65，负债权益比为 0.40。公司的 50 天简单移动平均线为$8.14，200 天简单移动平均线为$9.60。</p>
<p>药明康德集团（NASDAQ:PHAR - 获取免费报告）上次发布财报是在 8 月 1 日星期四。公司当季每股收益为（$0.01）。药明康德集团的净资产收益率为-5.69%，净利润率为-4.65%。该季度公司的营收为 7409 万美元，而分析师预期为 7195 万美元。去年同期，该公司每股收益为$0.02。研究分析师预测，药明康德集团今年财年每股盈利将为-0.03 美元。</p>
<h2>机构资金流入和流出</h2>
<p>一家对冲基金最近增加了对药明康德集团股票的持股。Silverberg Bernstein Capital Management LLC 根据最新提交给证券交易委员会的 13F 文件显示，该基金在第二季度增持了药明康德集团（NASDAQ:PHAR - 免费报告）的股份，增幅为 32.3%。该机构投资者在该时期内新增了 5725 股，持有公司股票 23435 股。Silverberg Bernstein Capital Management LLC 持有的药明康德集团股份价值 196,000 美元。目前有 0.03% 的股份由机构投资者和对冲基金持有。</p>
<h2>药明康德集团公司简介（获取免费报告）</h2>
<p>药明康德集团 N.V.是一家生物制药公司，致力于开发和销售用于治疗罕见疾病的蛋白替代疗法和精准药物，在美国、欧洲和国际市场销售。该公司提供 RUCONEST，一种重组 C1 酯酶抑制剂，用于治疗成年和青少年急性家族性性水肿（HAE）患者的急性发作；以及 Joenja（leniolisib），一种口服小分子 PI3Kδ抑制剂，用于治疗活化磷脂酰肌醇 3-激酶δ综合征。</p>
<h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票</li>
<li>3 家健康押息股票值得购买</li>
<li>Target 击中目标：第二季度盈利超出预期</li>
<li>如何开始投资房地产</li>
<li>特斯拉的反弹刚刚开始？为什么你应该考虑购买</li>
<li>投资者必须了解的场外交易股票</li>
<li>Stanley Druckenmiller 的最新赌注：MELI—你应该跟随吗？</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 精英们的阴谋：控制特朗普和你的金钱！（来自 Golden Crest）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg0"/></p>
<h2>您现在是否应该投资$1,000 购买药明康德集团股票？</h2>
<p>在考虑购买药明康德集团股票之前，您可能需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而药明康德集团不在名单上。</p>
<p>尽管药明康德集团目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PHAR

<p>Pharming Group（纳斯达克股票代码：PHAR）经历了异常高的交易量，约有 10,737 股交易，较上一交易日增长了 148%。该股最新交易价为$0.18，低于上一交易日的$0.82。HC Wainwright 的分析师维持了对该股的 “买入” 评级，并设定目标价为$1.00。Pharming 上季度报告的营收为 509 万美元，低于预期。该公司的市值为 2.8787 亿美元，以在罕见疾病领域的生物制药开发而闻名。机构投资者持有该股的 0.03%，最近注意到了持股的重大变化</p>

<p>Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 10,737 shares were traded during mid-day trading, an increase of 148% from the previous session's volume of 4,336 shares.The stock last traded at $8.18 and had previously closed at $7.82.</p>
<div class="lb-trans"><p>药明康德集团股票（NASDAQ:PHAR - 获取免费报告）周三交易量不寻常地高。大约有 10,737 股在午间交易时交易，较前一交易日的 4,336 股增加了 148%。该股最新交易价为$8.18，之前收盘价为$7.82。</p>
</div><p>Get <strong>Pharming Group</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>药明康德集团</strong> 警报：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Separately, HC Wainwright reiterated a &#34;buy&#34; rating and issued a $37.00 target price on shares of Pharming Group in a research report on Thursday, August 1st.</p>
<div class="lb-trans"><p>另外，HC Wainwright 重申了对药明康德集团股票的 “买入” 评级，并在 8 月 1 日星期四的研究报告中发布了 37.00 美元的目标价。</p>
</div><p><strong>Check Out Our Latest Research Report on Pharming Group</strong></p>
<div class="lb-trans"><p><strong>查看我们对药明康德集团的最新研究报告</strong></p>
</div><h2>Pharming Group Stock Up 4.6 %</h2>
<div class="lb-trans"><h2>药明康德集团股价上涨 4.6%</h2>
</div><p>The firm has a market cap of $550.87 million, a P/E ratio of -48.88 and a beta of 0.15. The company has a current ratio of 3.39, a quick ratio of 2.65 and a debt-to-equity ratio of 0.40. The company's 50 day simple moving average is $8.14 and its 200-day simple moving average is $9.60.</p>
<div class="lb-trans"><p>该公司市值为 5.5087 亿美元，市盈率为-48.88，β系数为 0.15。公司的流动比率为 3.39，速动比率为 2.65，负债权益比为 0.40。公司的 50 天简单移动平均线为$8.14，200 天简单移动平均线为$9.60。</p>
</div><p>Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The company had revenue of $74.09 million during the quarter, compared to analysts' expectations of $71.95 million. During the same period last year, the firm posted $0.02 EPS. Research analysts forecast that Pharming Group will post -0.03 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>药明康德集团（NASDAQ:PHAR - 获取免费报告）上次发布财报是在 8 月 1 日星期四。公司当季每股收益为（$0.01）。药明康德集团的净资产收益率为-5.69%，净利润率为-4.65%。该季度公司的营收为 7409 万美元，而分析师预期为 7195 万美元。去年同期，该公司每股收益为$0.02。研究分析师预测，药明康德集团今年财年每股盈利将为-0.03 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 32.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,435 shares of the company's stock after acquiring an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC's holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家对冲基金最近增加了对药明康德集团股票的持股。Silverberg Bernstein Capital Management LLC 根据最新提交给证券交易委员会的 13F 文件显示，该基金在第二季度增持了药明康德集团（NASDAQ:PHAR - 免费报告）的股份，增幅为 32.3%。该机构投资者在该时期内新增了 5725 股，持有公司股票 23435 股。Silverberg Bernstein Capital Management LLC 持有的药明康德集团股份价值 196,000 美元。目前有 0.03% 的股份由机构投资者和对冲基金持有。</p>
</div><h2>Pharming Group Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>药明康德集团公司简介（获取免费报告）</h2>
</div><p>Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.</p>
<div class="lb-trans"><p>药明康德集团 N.V.是一家生物制药公司，致力于开发和销售用于治疗罕见疾病的蛋白替代疗法和精准药物，在美国、欧洲和国际市场销售。该公司提供 RUCONEST，一种重组 C1 酯酶抑制剂，用于治疗成年和青少年急性家族性性水肿（HAE）患者的急性发作；以及 Joenja（leniolisib），一种口服小分子 PI3Kδ抑制剂，用于治疗活化磷脂酰肌醇 3-激酶δ综合征。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Pharming Group</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>Target Hits the Mark: Q2 Earnings Exceed Expectations</li>
<li>How to Start Investing in Real Estate</li>
<li>Is Tesla’s Rebound Just Starting? Why You Should Consider Buying</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>Stanley Druckenmiller's Latest Bet: MELI—Should You Follow Suit?</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票</li>
<li>3 家健康押息股票值得购买</li>
<li>Target 击中目标：第二季度盈利超出预期</li>
<li>如何开始投资房地产</li>
<li>特斯拉的反弹刚刚开始？为什么你应该考虑购买</li>
<li>投资者必须了解的场外交易股票</li>
<li>Stanley Druckenmiller 的最新赌注：MELI—你应该跟随吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Elites' Plot: Control Trump and YOUR Money! (From Golden Crest)(Ad)</p>
<div class="lb-trans"><p>→ 精英们的阴谋：控制特朗普和你的金钱！（来自 Golden Crest）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTg0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9184&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Pharming Group right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资$1,000 购买药明康德集团股票？</h2>
</div><p>Before you consider Pharming Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买药明康德集团股票之前，您可能需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而药明康德集团不在名单上。</p>
</div><p>While Pharming Group currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管药明康德集团目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Pharming Group（纳斯达克：PHAR）交易量异常高